DENVER, Colo. (247marketnews.com) -- Vera Therapeutics (NASDAQ:VERA) has delivered the kind of clinical readout that can fundamentally change the investment narrative around a commercial-stage biotech: its TRUTAKNA (atacicept-vymj) program has produced two-year data showing stabilization of kidney function and a dramatic reduction in kidney disease progression in patients with IgA nephropathy (IgAN).
In the final efficacy analysis of the 428-patient ORIGIN 3 study, TRUTAKNA produced an annualized eGFR decline of just 0.6 mL/min/1.73m² per year, compared with 5.6 for placebo, a placebo-adjusted treatment effect of 5.0 mL/min/1.73m² per year. Even more striking, the composite kidney disease progression endpoint occurred in 11 TRUTAKNA patients versus 38 on placebo, translating into a 76% reduction in risk with a hazard ratio of 0.24.
No patients receiving TRUTAKNA reached the composite endpoint of dialysis for at least 30 days, transplant or death, compared with eight placebo patients.
Those numbers matter because Vera is attempting to move TRUTAKNA beyond its current accelerated approval based on proteinuria reduction and toward a broader demonstration of clinical benefit. The FDA approved TRUTAKNA in July 2026 to reduce proteinuria in adults with primary IgAN at risk for disease progression, but explicitly noted that long-term kidney-function benefit had not yet been established.
The new ORIGIN 3 results directly address that central question.
“The ORIGIN 3 final analysis, demonstrating a significant reduction in risk of composite kidney disease progression, true stabilization of eGFR, and a favorable safety profile through two years, marks a milestone in IgAN treatment,” said Richard Lafayette, M.D., F.A.C.P., a Stanford nephrologist and ORIGIN 3 principal investigator.
Vera now plans to submit a supplemental Biologics License Application to the FDA in the fourth quarter of 2026, potentially setting the stage for full approval in 2027. The company had already reached agreement with the FDA to pull the eGFR analysis forward from 2027 into the third quarter of 2026, making this readout a pivotal regulatory catalyst.
The commercial story is moving just as quickly. Vera says the first ten weeks of the TRUTAKNA launch generated more than 350 patient start forms, with paid claims emerging and initial payer policies described by management as encouraging. TRUTAKNA is administered once weekly at home through an autoinjector, potentially giving the company a relatively convenient commercial proposition in a serious kidney disease with substantial unmet need.
“We are excited for the upcoming supplemental BLA submission based on the ORIGIN 3 final analysis,” said Matt Skelton, Vera’s chief commercial officer. “The early momentum of the TRUTAKNA launch is very encouraging.”
TRUTAKNA remains approved under the accelerated-approval pathway for reduction of proteinuria, and the FDA requires verification of clinical benefit for continued approval. The latest ORIGIN 3 data could provide the evidence Vera needs for that next step, but the supplemental application and FDA review remain ahead.
Important Editorial Note: 247 highlights companies approaching significant catalysts and inflection points. This report reflects information available at the time of publication. Since developments can occur rapidly, readers should independently verify current information and review all company filings and disclosures.